Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avant’s oral typhoid vaccine meets Phase II endpoints
The endpoints of the out-patient, dose-ranging Phase II study were to determine the optimal dose of Ty800 for further development based on the safety, reactogenicity, and immunogenicity of
The endpoints of the out-patient, dose-ranging Phase II study were to determine the optimal dose of Ty800 for further development based on the safety, reactogenicity, and immunogenicity of
Additionally, Ranexa has significantly improved all measures of exercise performance compared to placebo, including reductions in the time to onset of angina (p=0.002) and time to the onset
The technology was discovered and patented by the Pharmaceutical Research Institute of Warsaw Poland and involves compounds that appear to be novel antimicrotubule agents. Donald Picker, president and
Under terms of this new agreement, Breckenridge will submit an abbreviated new drug application (ANDA) to the FDA for the product which will be developed by Helm. The
The study (DUAAL study) was a randomized, double-blind, multi-country study comparing Lipitor (n=103), Norvasc (amlodipine besylate) (n=104) and a combination of the two (n=104) in patients with coronary
Pursuant to the terms of the agreement, SciGen will seek governmental approvals for the sale of Generex Oral-lyn in the territory using SciGen’s own recombinant human insulin product.
The findings demonstrated equivalence between the 0.18% formulation and company’s 0.09% formulation of Xibrom given once daily in achieving the primary efficacy endpoint of absence of ocular inflammation
The acquisition includes the Empower line of contrast injector delivery systems, IRiS contrast management system and the EZ Chem point-of-care device, a unique chemistry device for testing serum
Pfizer has communicated with worldwide regulatory authorities and investigators regarding the discontinuation of the trial. Investigators will work with their patients to determine if they are benefiting from
The transaction is scheduled to close on April 30, 2008 pending regulatory approval. The acquisition will include the relevant business, customer contracts, associated products, process technology, intellectual property,